A Texas jury in April awarded Seagen nearly $42 million from Daiichi Sankyo over claims that Daiichi and AstraZeneca plc's breast-cancer drug Enhertu violated Seagen's patent rights.
(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5,502 JPY | +3.13% | +9.82% | +42.10% |
04-30 | Remsons, Daiichi Infotainments Form Joint Venture | MT |
04-29 | AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement | MT |
(Reuters) - Seagen Inc said on Friday an arbitrator had ruled in favor of Japan's Daiichi Sankyo over an agreement between the two companies for using Seagen's drug technology.
A Texas jury in April awarded Seagen nearly $42 million from Daiichi Sankyo over claims that Daiichi and AstraZeneca plc's breast-cancer drug Enhertu violated Seagen's patent rights.
(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)
1st Jan change | Capi. | |
---|---|---|
+42.10% | 69B | |
+26.08% | 662B | |
+21.56% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 289B | |
+13.68% | 234B | |
+4.57% | 198B | |
-10.72% | 194B | |
+8.08% | 167B |